Atopic Dermatitis Ad clinical trials

Explore recruiting atopic dermatitis ad clinical trials.

Recruiting atopic dermatitis ad studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Atopic Dermatitis Ad trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized, Double-Blind, Placebo-Controlled Phase 2a Proof of Concept Study Evaluating the Safety and Efficacy of ADX-914 in Subjects with Moderate to Severe Atopic Dermatitis

Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Open-label, 52-week Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab (AMG 451) in Adolescent Subjects Aged ≥ 12 to < 18 years With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Orbit)

Portugal, Hungary, Denmark, Germany, Italy, Austria +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

The effect of SYX-5219 on an immune response in the skin.

Netherlands

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis

Netherlands, Spain, France, Italy, Germany, Bulgaria +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Participants with Moderate-to-Severe Atopic Dermatitis

Germany, Poland

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Rerandomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO)

Croatia, Italy, Hungary, Poland, Romania, Belgium +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Atopic Dermatitis Ad trials by city

Atopic Dermatitis Ad clinical trials

Recruiting atopic dermatitis ad studies right now

Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD

CeraVe Effect on Restoring Skin Hydration as Maintenance Regimen in Subjects With Mild to Moderate Atopic Dermatitis

A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis

A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab

A Phase I Study of SSGJ-716 in Healthy Adults and Participants With Moderate-to-Severe Atopic Dermatitis

A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis.

Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234

Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD.

A Phase 1 Clinical Study Comparing GS101 and Dupixent® After Subcutaneous Injection

A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis

Also recruiting in Europe

A Randomized, Double-Blind, Placebo-Controlled Phase 2a Proof of Concept Study Evaluating the Safety and Efficacy of ADX-914 in Subjects with Moderate to Severe Atopic Dermatitis

A Phase 3, Open-label, 52-week Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab (AMG 451) in Adolescent Subjects Aged ≥ 12 to < 18 years With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Orbit)

The effect of SYX-5219 on an immune response in the skin.

A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis

A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Participants with Moderate-to-Severe Atopic Dermatitis

A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Rerandomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO)

Atopic Dermatitis Ad trials by city

Other conditions